Zibotentan plus dapagliflozin shows no HVPG reduction in compensated cirrhosis
Early trial shows zibotentan plus dapagliflozin trended toward lowering blood pressure in cirrhosis patients
This Phase II randomized placebo-controlled exploratory study in 28 patients with compensated cirrhosis found that zibotentan 2.5 mg plus da…
An early study found that a combination drug lowered blood pressure in patients with compensated cirrhosis, though it did not conclusively i…
Influenza vaccine induces stronger immune responses in liver cirrhosis patients
Flu Shot Works Better in Advanced Liver Disease
This prospective observational study found that patients with liver cirrhosis mount stronger humoral and cell-mediated immune responses to t…
You’re living with cirrhosis. Every cold feels dangerous.
Seladelpar shows improved composite endpoint and ALP reduction in PBC with compensated cirrhosis
New Drug Helps Liver Disease Patients With Cirrhosis
A phase 3 RCT program (RESPONSE and ASSURE studies) in patients with primary biliary cholangitis and compensated cirrhosis found seladelpar …
A new drug lowers liver stress markers in patients with cirrhosis, offering hope where older medicines often failed to stop disease progress…
Research across Cirrhosis
Related studies from across the Cirrhosis family.
Prolonged SEMS retention for refractory variceal bleeding allows removal after 387 days
Doctors successfully remove a metal stent after one year of use
This case report describes a 72-year-old woman with decompensated cirrhosis who received a fully covered self-expanding metal stent (SEMS) f…
A new case report shows a metal stent can be safely removed after a year of use, offering a possible path for patients with liver disease.
Multidrug-resistant pathogens are prevalent in cirrhosis with higher rates in lower-middle-income countries
Gram-negative Bacteria and Resistance Patterns in Cirrhosis Patients
This systematic review and proportional meta-analysis of 2781 clinical infections and 381 colonizations in adults with cirrhosis identifies …
A large review of infections in patients with cirrhosis shows that 60% of bacterial isolates are Gram-negative and many show drug resistance…
Non-selective beta-blockers reduce mortality risk by 25% in patients with decompensated cirrhosis
Beta Blockers May Reduce Mortality Risk in Cirrhosis Patients
This meta-analysis of observational studies involving 120,072 patients found that non-selective beta-blockers (NSBBs) are associated with a …
A large-scale review suggests that non-selective beta-blockers may lower mortality risks for patients with decompensated cirrhosis, especial…
Sarcopenia Assessment Modalities and Mortality Risk Prediction in Patients with Liver Cirrhosis
Muscle Loss Linked to Higher Mortality Risk in Liver Cirrhosis
Meta-analysis confirms that sarcopenia significantly increases mortality risk in liver cirrhosis patients across multiple imaging and physic…
Patients with liver cirrhosis and muscle loss, known as sarcopenia, face a significantly higher risk of mortality across several different m…
Multidisciplinary teams and bloodless medicine pathways may improve outcomes for acute gastrointestinal bleeding
New research looks at better ways to treat internal bleeding
This systematic review synthesizes evidence on organizational models, such as multidisciplinary team programs and transfusion-free pathways,…
Specialized team-based care and bloodless medicine pathways show promise for patients with serious gastrointestinal bleeding.
Direct oral anticoagulants reduce thrombotic events and major bleeding in cirrhosis with atrial fibrillation or venous thromboembolism
Direct oral anticoagulants show promise for patients with liver cirrhosis
A meta-analysis of predominantly observational studies compared direct oral anticoagulants with traditional anticoagulants in patients with …
New analysis suggests direct oral anticoagulants may reduce blood clots and major bleeding risks for patients with liver cirrhosis and heart…
Multidrug-resistant bacterial infections are prevalent among hospitalized patients with cirrhosis
Analysis shows high rates of drug resistant infections in cirrhosis
This meta-analysis examined the prevalence of multidrug-resistant bacterial infections in hospitalized patients with cirrhosis. The findings…
Over one-third of hospitalized patients with liver cirrhosis face infections from bacteria that are hard to treat with standard medications.
Carvedilol and endoscopic variceal ligation show similar efficacy for preventing variceal bleeding in cirrhosis
Comparing Carvedilol and Endoscopic Procedures to Prevent Bleeding in Liver Cirrhosis
This meta-analysis of randomized controlled trials involving 1385 patients found no significant difference between carvedilol and endoscopic…
Doctors are looking at whether the drug carvedilol works as well as endoscopic procedures to stop dangerous bleeding in patients with liver …
Viscoelastic Testing Cuts Transfusions in Cirrhosis Procedures
New testing method reduces blood transfusions for liver patients
Meta-analysis finds VET-guided transfusions reduce blood product use without raising bleeding risk in cirrhotic patients undergoing procedur…
A new testing method helps patients with cirrhosis receive fewer blood transfusions during invasive procedures without increasing their risk…
Exercise programs improve muscle mass and physical performance indicators in patients with liver cirrhosis
Exercise improves muscle strength in cirrhosis patients
This meta-analysis of 16 studies involving 942 patients found that exercise interventions significantly improved 6-min walk distance, thigh …
Exercise boosts muscle mass and walking ability in people with cirrhosis and muscle loss, a new analysis finds.
GLP-1RAs show lower risk of serious liver events compared with DPP-4 inhibitors in adults with type 2 diabetes
GLP-1 drugs may lower serious liver risks compared to DPP-4 inhibitors in type 2 diabetes
This systematic review and exploratory meta-analysis evaluated incident cirrhosis or composite serious liver events among adults with type 2…
A new analysis suggests GLP-1 receptor agonists might reduce serious liver events compared to DPP-4 inhibitors for adults with type 2 diabet…
Hepatologist-led palliative care matches specialist care for cirrhosis and cancer patients
Trained liver doctors provided care that matched specialists for patients with serious liver disease
A US trial found hepatologist-delivered palliative care noninferior to specialist care for improving quality of life in advanced liver disea…
Patients with advanced liver disease saw similar quality of life improvements when cared for by trained liver doctors versus specialists. Bo…